These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38796287)

  • 1. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
    Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
    Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
    Iwata H; Xu B; Kim SB; Chung WP; Park YH; Kim MH; Tseng LM; Chung CF; Huang CS; Kim JH; Chiu JWY; Yamashita T; Li W; Egorov A; Nishijima S; Nakatani S; Nishiyama Y; Sugihara M; Cortés J; Im SA
    Cancer Sci; 2024 Jul; ():. PubMed ID: 38979893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Hurvitz SA; Hegg R; Chung WP; Im SA; Jacot W; Ganju V; Chiu JWY; Xu B; Hamilton E; Madhusudan S; Iwata H; Altintas S; Henning JW; Curigliano G; Perez-Garcia JM; Kim SB; Petry V; Huang CS; Li W; Frenel JS; Antolin S; Yeo W; Bianchini G; Loi S; Tsurutani J; Egorov A; Liu Y; Cathcart J; Ashfaque S; Cortés J
    Lancet; 2023 Jan; 401(10371):105-117. PubMed ID: 36495879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
    Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
    Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
    Ciapponi A; Bardach A; Colaci C; Rodríguez Cairoli F; Argento F; Korbenfeld E; García Martí S
    Rev Peru Med Exp Salud Publica; 2024 May; 41(1):7-18. PubMed ID: 38808848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
    Cortés J; Hurvitz SA; Im SA; Iwata H; Curigliano G; Kim SB; Chiu JWY; Pedrini JL; Li W; Yonemori K; Bianchini G; Loi S; Borges GS; Wang X; Bachelot T; Nakatani S; Ashfaque S; Liang Z; Egorov A; Hamilton E
    Nat Med; 2024 Jun; ():. PubMed ID: 38825627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
    Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
    Hu S; Wu Y; Luan J; Wang S; Fan G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
    Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
    Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
    [No Abstract]   [Full Text] [Related]  

  • 15. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
    Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
    Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-DXd Keeps Shining in Breast Cancer.
    Cancer Discov; 2023 Feb; 13(2):254. PubMed ID: 36484540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Wang M; Wang K; Zhu H
    Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
    Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
    Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.